NewLink Genetics Corp (NLNK):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】NewLink Genetics Corp (NLNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9807)・商品コード:DATA904C9807
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:62
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
NewLink Genetics Corp (NewLink) is a clinical stage immuno-oncology company that discovers and develops novel immunotherapeutic products for the treatment of cancer. Its products include small-molecule and biologic immuno-oncology products. NewLink utilizes its HyperAcute cellular immunotherapy technology and IDO pathway inhibitor technology to develop biologic product candidates and small-molecule product candidates, respectively. The company’s pipeline products include indoximod and NLG919. It has two HyperAcute Cellular Immunotherapy product candidates in clinical development: tergenpumatucel-L for treatment of advanced lung cancer and dorgenmeltucel-L for melanoma. Algenpantucel-L, Tergenpumatucel-L and Dorgenmeltucel-L. The company also develops and commercializes vaccines for the treatment of infectious diseases using its HyperAcute technology. The company has operations in the US and the UK. NewLink is headquartered in Ames, Iowa, the US.

NewLink Genetics Corp (NLNK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11
Partnerships 13
NewLink Genetics Enters into Agreement with AstraZeneca 13
NewLink Genetics Enters into Agreement with BARDA 14
Licensing Agreements 15
NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15
NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16
Merck Enters into Licensing Agreement with NewLink Genetics 17
NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19
NewLink Genetics Enters into Licensing Agreement with Ohio State University 20
Equity Offering 21
NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21
NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22
NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23
NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25
NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To US$60 Million 26
NewLink Genetics Completes Public Offering Of Shares For US$52 Million 27
NewLink Genetics Corp – Key Competitors 28
NewLink Genetics Corp – Key Employees 29
NewLink Genetics Corp – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 02, 2018: Newlink Genetics reports third quarter 2018 financial results and announces abstracts to be presented at upcoming medical meetings 31
Jul 31, 2018: NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance 33
May 03, 2018: NewLink Genetics Reports First Quarter 2018 Financial Results 35
Mar 01, 2018: NewLink Genetics Announces Fourth Quarter And Year End 2017 Financial Results 36
Nov 02, 2017: NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program 37
Jul 28, 2017: NewLink Genetics Reports Second Quarter 2017 Financial Results 39
Jul 28, 2017: NewLink Genetics Q2 net loss decreases 40
May 04, 2017: NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance 41
Feb 28, 2017: NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results 42
Corporate Communications 43
May 01, 2018: NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors 43
Mar 21, 2018: NewLink Genetics Appoints Chad A. Johnson to Board of Directors 44
Nov 14, 2017: NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer 45
Product Approvals 46
Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 46
Clinical Trials 47
Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors 47
Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children 48
Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma 49
Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program 50
Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802 51
Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain 52
Jun 05, 2017: NewLink Genetics’ Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial 53
Jun 02, 2017: Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer 54
May 18, 2017: Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress 55
May 17, 2017: Data from Clinical Study of NewLink Genetics’ Indoximod to Be Presented at ASCO 2017 56
May 17, 2017: Data from Clinical Study of NewLink Genetics’ Navoximod to Be Presented at ASCO 2017 57
Apr 21, 2017: NewLink Genetics Presents Pipeline Drug Indoximod at ASCO 58
Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 59
Apr 04, 2017: Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary 60
Mar 01, 2017: NewLink Genetics Announces Presentation of Two Abstracts at AACR 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NewLink Genetics Corp, Deals By Therapy Area, 2012 to YTD 2018 9
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11
NewLink Genetics Enters into Agreement with AstraZeneca 13
NewLink Genetics Enters into Agreement with BARDA 14
NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15
NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16
Merck Enters into Licensing Agreement with NewLink Genetics 17
NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19
NewLink Genetics Enters into Licensing Agreement with Ohio State University 20
NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21
NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22
NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23
NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25
NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To US$60 Million 26
NewLink Genetics Completes Public Offering Of Shares For US$52 Million 27
NewLink Genetics Corp, Key Competitors 28
NewLink Genetics Corp, Key Employees 29
NewLink Genetics Corp, Other Locations 30
NewLink Genetics Corp, Subsidiaries 30

List of Figures
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[NewLink Genetics Corp (NLNK):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9807)販売に関する免責事項を必ずご確認ください。
★調査レポート[NewLink Genetics Corp (NLNK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆